MATW — Matthews International Corporation

Matthews International's core memorialization business — supplying caskets, cemetery memorials, cremation equipment, and now the largest embalming chemical supplier in North America — generates $810 million in annual revenue at roughly 21% EBITDA margins and is more durable than the chronic stock underperformance suggests. After two decades of misallocated capital that inflated debt to seven times EBITDA, a forced reckoning under activist pressure is unwinding the damage: $580 million in divestitures and more than $1 billion in debt reduction in a single year, leaving a focused business trading at 7.5 times adjusted EBITDA with an option on proprietary dry battery electrode technology whose $100 million-plus customer quote pipeline is frozen by a Tesla dispute whose resolution could change the value picture materially. The memorialization franchise deserves a better multiple than it has received, but eighteen years of compounded capital allocation errors — validated by 0.40% returns on invested capital — require more than one year of cleanup before the case for ownership is unambiguous.

---

The death care industry attracts almost no analytical attention despite being one of the most structurally predictable markets in the economy. Roughly 3.3 million Americans die each year, a number that is rising as the largest demographic cohort in American history moves through its seventies and eighties. The services and products surrounding death — funerals, caskets, urns, cemetery markers, embalming — are purchased under conditions that suppress price sensitivity: grief, time pressure, social obligation, and the one-time nature of the purchase combine to produce a market where customers rarely shop on price and rarely switch providers. Against this backdrop, the death care supply chain has quietly generated consistent revenue for the companies that operate within it, largely invisible to the broader investment community that finds the subject uncomfortable to contemplate.

The structural shift reshaping this market is the rise of cremation. The cremation rate in the United States has risen from roughly 27% in 2000 to approximately 60% in 2023 and is projected by the National Funeral Directors Association to reach 82% by 2045. This trend is an unambiguous headwind for casket manufacturers — a cremated body requires no casket — and a tailwind for cremation equipment manufacturers, urn makers, and providers of cremation accessories. The companies best positioned for the next two decades are those that have moved beyond the casket as their primary product. Matthews International has been making this transition, though its execution has been obscured by a simultaneous and ultimately destructive decision to diversify the company into entirely unrelated businesses.

The memorialization supply chain in the United States is concentrated. Batesville, which operated as the funeral segment of Hillenbrand Corporation before being taken private, has historically held the largest share of the casket market. Matthews International is the other major national supplier, with a portfolio spanning caskets, bronze and granite cemetery memorials, cremation equipment, and now embalming chemicals and funeral supplies through its May 2025 acquisition of The Dodge Company for $57 million. Service Corporation International, the largest funeral home operator with over 1,900 locations, operates on the services side of the market but does not compete with Matthews in manufacturing or supply. The supply chain structure is favorable: funeral homes require reliable, relationship-based vendors who understand the operational requirements of the death care business, and switching suppliers for products used in the context of grief requires a level of disruption that most operators avoid. Matthews has deepened this relationship systematically — from casket to memorial to cremation equipment to embalming supply, the company now touches nearly every product a funeral home purchases in the normal course of its operations.

The Dodge Company acquisition illustrates both the quality of the memorialization franchise and the strategic direction that management would have pursued sooner had the balance sheet been in better condition. Founded in 1893, Dodge is the largest supplier of embalming chemicals and cosmetics in North America, selling to the same funeral home and cemetery customer base that purchases Matthews caskets and memorials. The acquisition price of $57 million for the market-leading supplier of a consumable product purchased on a recurring basis — funeral directors buy embalming chemicals for every body they prepare — represents exactly the type of bolt-on that deepens pricing power and customer retention without adding operating complexity. Integration synergies were reported ahead of plan in Q4 FY2025, and the segment's EBITDA margin expanded to 21.5% from 20.6% the prior year — demonstrating pricing power in a year when U.S. death rates declined from elevated post-COVID levels back toward the long-term average. The business raised prices faster than volume fell, which is the simplest possible demonstration of a durable competitive position.

The financial profile of Matthews International is not, at first glance, the picture of a durable franchise. Total revenue has been declining for several years, reported earnings have been negative on a GAAP basis, and operating cash flow turned sharply negative in the first quarter of fiscal 2026. These figures require context. Matthews has been unwinding a decade-long diversification experiment that added three businesses to the core memorialization operation: SGK Brand Solutions (packaging design and brand services), a warehouse automation division, and a European packaging business. None of these had a natural relationship to the funeral supply chain. All were financed with debt. The SGK business was sold in May 2025, with Matthews retaining a 40% stake in the successor entity Propelis. The warehouse automation business was sold to Duravant for $232 million, closing December 31, 2025. The European packaging business was divested in the first quarter of fiscal 2026. The combined proceeds from these transactions have been directed entirely to debt retirement: net debt fell from approximately $1.35 billion at the end of fiscal 2024 to $711 million at September 30, 2025, to $537 million at December 31, 2025 — a reduction of more than $800 million in fifteen months.

The negative operating cash flow in Q1 fiscal 2026 is a product of the transition, not the underlying business. Divestiture-related legal costs, transaction fees, restructuring charges, and the temporary mismatch between when operating expenses are recognized and when working capital normalizes in a shrinking company have all compressed reported cash flow. The adjusted EBITDA for the quarter was $35.2 million, down from $40 million in the prior year, reflecting the loss of divested segment contributions. Management maintained guidance of at least $180 million in adjusted EBITDA for the full fiscal year 2026 — a figure that includes the company's estimated 40% share of Propelis adjusted EBITDA — against an enterprise value of approximately $1.36 billion. That is 7.5 times forward adjusted EBITDA. For context, Service Corporation International, a structurally similar business in the death care ecosystem, trades at approximately 13 to 15 times EBITDA. Matthews trades at a 40 to 50% discount to the most relevant comparable.

The number that explains the discount is 0.40%. That is Matthews' return on invested capital as of the most recent measurement period — a figure that reflects not just cyclical weakness but the structural consequence of a management team that spent years acquiring businesses at high prices with debt, generating returns well below the cost of that capital. Barington Capital, an activist investor that began agitating for change in 2024, described eighteen years of stock underperformance and demanded a board overhaul, the consideration of a sale of the company, and a return to capital discipline. The company has since added four new independent directors since 2023, appointed J. Michael Nauman as non-executive chairman, agreed to eliminate the staggered board structure, and adopted majority voting for director elections — governance reforms that would not have materialized without the activist pressure. In January 2026, after two rounds of proxy fights, Matthews announced an agreement with Barington in which the activist withdrew its nominations in exchange for the reforms already underway.

CEO Joseph C. Bartolacci has led the company since 2006 — the same tenure during which the ROIC deteriorated, the debt accumulated, and the diversification occurred. The $490 million returned to shareholders through dividends and share repurchases since 2014 is a real number, but it was generated against a backdrop of capital destruction elsewhere in the portfolio that more than offset it. The current dividend of $0.255 per share quarterly ($1.02 annualized) yields approximately 3.9% at the current price, which is genuine compensation for waiting. The acquisitions of SGK and the warehouse automation business were funded at prices that have not been recouped; the Dodge Company acquisition, at $57 million for a durable recurring-revenue business, is a different category of decision. The question is whether the twelve months of forced rationalization under activist pressure represent a genuine shift in how the company allocates capital, or a temporary response that will reverse when the external pressure dissipates.

The growth trajectory of the memorialization segment alongside the corporate leverage history tells the story most clearly:

Fiscal Year	Total Revenue	Adj. EBITDA	Net Debt	Net Leverage
FY2022	~$1.87B	~$228M	~$1.75B	~7.7x
FY2023	~$1.82B	~$208M	~$1.54B	~7.4x
FY2024	~$1.73B	~$193M	~$1.35B	~7.0x
FY2025	~$1.67B	$200M	$711M	~3.6x
FY2026E	~$960M*	≥$180M	<$537M	<3.0x

FY2022–FY2024 figures are approximate estimates based on public disclosures and Barington Capital's investor materials. FY2025 and FY2026E figures reflect company guidance. *FY2026E revenue reflects the post-divestiture continuing business; comparison to prior years is not meaningful on a like-for-like basis.

The table compresses two stories. The first is a slow-motion capital structure deterioration: leverage sat above 7 times EBITDA for years while the company made acquisitions and maintained its dividend, the equity value gradually eroded by the interest burden and the below-cost-of-capital returns on deployed capital. The second story is the abruptness of the reversal: from 7.7 times EBITDA to below 3 times in two years, driven by asset sales at what management describes as accretive valuations. Matthews sold SGK, warehouse automation, and European packaging at a combined value of approximately $580 million — businesses that together generated perhaps $95 million in EBITDA, implying an exit multiple of roughly 6 times. The seller's terms were not exceptional, but the strategic logic of the exits is correct: the leverage ratio is now approaching a level where the company can reinvest in the memorialization core without debt service consuming the majority of cash flow.

The penetration argument for memorialization is unusual in that it is not primarily about underpenetrated markets — it is about deepening the relationship with an already-captive customer base. Matthews' memorialization products touch approximately 50 to 60% of the deaths that occur in the United States each year through some combination of caskets, memorials, or cremation equipment. The immediate growth opportunity is not expanding to new funeral homes — the customer base is largely established — but expanding the revenue per funeral home as Matthews adds products (Dodge embalming supply is the clearest example) and as cremation volumes increase the demand for cremation-specific products where Matthews is investing. The long-term structural opportunity is the conversion of the approximately 40% of deaths that still involve burial; as those customers transition to cremation over the next two decades, the market does not shrink — it migrates from one product category to another, and Matthews is positioned on both sides.

The optionality in the Industrial Technologies segment introduces a different category of value — one that is genuinely difficult to price because the dispute with Tesla has injected legal uncertainty into what would otherwise be a compelling commercial story. Matthews has spent approximately twenty years developing proprietary dry battery electrode technology, which eliminates the solvent-based wet process used in traditional lithium-ion battery electrode manufacturing. The wet process requires enormous facilities with ovens to drive off the solvent; DBE technology eliminates both the solvent and the ovens, reducing capital costs, energy consumption, and factory footprint substantially. Tesla became a development partner, then sued Matthews in June 2024, claiming Matthews had stolen trade secrets related to Tesla's 4680 battery electrode technology and seeking more than $1 billion in damages. In February 2026, an arbitrator issued an interim ruling that denied Tesla's request for broad injunctive relief and affirmed Matthews' right to sell its DBE equipment — though Tesla immediately disputed this characterization, claiming the ruling constituted a permanent injunction against further misappropriation. Both parties are continuing to contest the interpretation as of March 2026.

The DBE situation is the central binary in the investment case. If Matthews' ownership of the DBE technology is ultimately affirmed and the commercial pipeline converts to orders, the $100 million-plus in customer quotes accumulated since February 2025 could represent the beginning of a fundamentally different revenue stream — battery manufacturers seeking to reduce their electrode manufacturing costs would find the technology compelling regardless of who developed the underlying science. If Tesla's $1 billion damages claim succeeds, the liability would exceed the current equity market capitalization of the company. The interim arbitration ruling appears to favor Matthews on the commercial rights question, but the full litigation timeline could extend for years, and the uncertainty is a legitimate reason to discount the equity. At $26 per share, the market appears to be placing minimal value on DBE optionality while pricing the memorialization core at a significant discount to comparable businesses — a position that implies either the litigation risk is terminal or the asset simplification is not credible. Neither is obviously correct.

At approximately $26.29 per share, Matthews has a market capitalization of roughly $818 million and an enterprise value of approximately $1.36 billion after the Q1 fiscal 2026 debt reduction to $537 million. Against the fiscal 2026 EBITDA guidance of at least $180 million, the implied EV/EBITDA multiple is 7.5 times. With normalized D&A of approximately $55 to $65 million on the continuing asset base, EBIT runs roughly $115 to $125 million. At current debt levels and an average interest rate above 7% on legacy instruments (most of which have now been refinanced), interest expense is approximately $38 million annually and declining as the remaining balance comes down. Pre-tax earnings approach $80 million on a normalized basis, or approximately $2.60 per diluted share. At $26.29, the pre-tax multiple is roughly 10 times — below the 15 times threshold — and the pre-tax earnings yield of 9.9% against a 2.5% inflation rate produces a real return in the 5 to 6% range, easily satisfying the minimum requirement for a real return on capital. The price is not the problem. The question is whether the business will deliver those earnings consistently under the stewardship of the management team that created the leverage problem in the first place.

The intelligent bear argues that the Barington agreement and the governance reforms are a temporary accommodation by a management team that has demonstrated it will revert to value-destroying diversification once the activist pressure subsides — that the CEO who oversaw 18 years of ROIC destruction has not been replaced, that the board additions are incremental rather than structural, and that the DBE technology has been "about to monetize" for years without materializing. This is a credible argument and it explains the discount to SCI at 13x EBITDA. The answer is that the balance sheet simplification occurring right now — $1 billion in debt reduction in twelve months — is not reversible. The leverage that enabled the diversification mistakes has been structurally reduced. A management team that cannot take on new debt to make bad acquisitions is, at a minimum, less dangerous than one that can. The question is not whether to trust the same management team to make better decisions; it is whether the constraints now placed on that team — debt covenants, activist scrutiny, governance reforms — are sufficient to prevent a recurrence while the memorialization franchise compounds modestly.

Interesting but requires a specific catalyst to be actionable. The memorialization core, trading at 7.5 times EV/EBITDA against a business with 21% EBITDA margins and rising, is unambiguously cheap relative to the industry. The 3.9% dividend yield provides compensation for the wait. The DBE option, currently depressed by litigation uncertainty, represents asymmetric upside that costs nothing at the current price. What is missing is evidence: evidence that the management team has actually changed its capital allocation approach, not merely accommodated an activist temporarily; and evidence that the DBE technology has a viable commercial path that is not permanently clouded by the Tesla litigation. Both pieces of evidence are achievable in the next twelve to eighteen months — management's Q2 and Q3 fiscal 2026 decisions about how to deploy the divestiture proceeds will be the first test, and the continued clarification of the arbitration ruling will determine whether DBE customer quotes convert to orders.

What would change the verdict: a favorable resolution of the Tesla dispute, allowing DBE orders to convert from the current $100 million-plus quote pipeline to recognized revenue; or two consecutive fiscal years of positive free cash flow and declining leverage, demonstrating that the capital discipline is structural rather than situational; or a management change that brings in leadership with a demonstrably different approach to capital allocation. Any one of these would shift the case from "interesting but uncertain" to "compelling at the current price." At $26, the underlying business earns this patience. Whether the management team has earned it is the question that remains open.

The memorialization franchise has outlasted far more celebrated businesses since 1850. Whether the management team that nearly buried it under leverage and diversification will give it the focused stewardship it deserves — that verdict is still being written.